Alan Manevitz, MD
Psychiatry · New York, NYNPI 1093860975
Payments from drug & device makers
Across 163 payments — averaging $45.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$4K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$341
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$323
- Vanda Pharmaceuticals Inc.$214
- Johnson & Johnson$150
- plus $821 from 12 others
What the payments were for
- Food & beverage$3,15342%
- Education$1632%
- Other$4,12155%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 7 | $4,301 |
| AbbVie(2 entities) | 81 | $1,287 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $341 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $323 |
| Vanda Pharmaceuticals Inc. | 10 | $214 |
| Johnson & Johnson | 6 | $150 |
| Alkermes, Inc. | 6 | $147 |
| Bausch Health US, LLC | 6 | $141 |
| Supernus Pharmaceuticals, Inc. | 2 | $120 |
| Lundbeck LLC | 5 | $103 |
| Almatica Pharma LLC | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 2 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Livanova USA, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$4,121
- QELBREE$115
How this compares
$7,437 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 28 | $37,599 |
| ProzacFluoxetine Hcl | 37 | $19,340 |
| VyvanseLisdexamfetamine Dimesylate | 28 | $11,294 |
| SavellaMilnacipran Hcl | 29 | $9,439 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 135 | $7,333 |
| ZoloftSertraline Hcl | 18 | $7,299 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,680 |
| LexaproEscitalopram Oxalate | 11 | $5,581 |
| Lisdexamfetamine Dimesylate | 17 | $4,581 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 140 | $3,918 |
| DayvigoLemborexant | 11 | $3,641 |
| Quetiapine Fumarate | 249 | $3,356 |
| Clonazepam | 384 | $2,882 |
| Alprazolam | 215 | $2,696 |
| Olanzapine | 100 | $2,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Savella, Lexapro | $1,287 | $52,61968 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $341 | $17,97440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.